Posted by Michael Wonder on 18 Jan 2024
UCB announces MHRA approval for UCB’s Zilbrysq
18 January 2024 - Green light concerns generalised myasthenia gravis therapy
The MHRA has granted marketing authorisation for Zilbrysq as an add-on to standard therapy.
